BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//International Health Economics Association - ECPv6.15.11//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://healtheconomics.org
X-WR-CALDESC:Events for International Health Economics Association
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:UTC
BEGIN:STANDARD
TZOFFSETFROM:+0000
TZOFFSETTO:+0000
TZNAME:UTC
DTSTART:20250101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VTIMEZONE
TZID:UTC
BEGIN:STANDARD
TZOFFSETFROM:+0000
TZOFFSETTO:+0000
TZNAME:UTC
DTSTART:20250101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VTIMEZONE
TZID:America/Toronto
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20250309T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20251102T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20260308T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20261101T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20270314T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20271107T060000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=UTC:20260428T140000
DTEND;TZID=UTC:20260428T150000
DTSTAMP:20260425T064724
CREATED:20260402T152906Z
LAST-MODIFIED:20260407T180713Z
UID:334848-1777384800-1777388400@healtheconomics.org
SUMMARY:A new approach to comparing EQ-5D-5L value sets: What really makes a difference to people?
DESCRIPTION:Add to Calendar! \nBackground\nEQ-5D-5L value sets play a vital role worldwide in health technology assessment and measuring population health. However\, it is difficult to compare the impact of using different value sets\, for example if an older value set is replaced by a new one\, or if two or more value sets are available. \nObjectives\n1) Reformulating the standard EQ-5D-5L health-state utility model in terms of meaningful\, interpretable parameters: range of utility from best to worst state\, relative importance of each dimension\, and decrements associated with levels 2-4 as a fraction of the level 5 decrement;\n2) Providing formulae for the marginal effects of the reformulated model’s parameters on utilities;\n3) Empirically estimating marginal effects for several value sets and patient groups. \nData and Methods\nThe 2017/8 Health Surveys for England collected EQ-5D-5L responses from around 13\,000 people. Participants with a long-term condition were divided into patient groups according to how the condition affected them (vision/mobility/mental health/etc.). Participants with long-lasting pain were divided into groups of varying severity using the Chronic Pain Grade Scale (CPGS). The marginal effects of parameters from 48 EQ-5D-5L value sets were calculated for each patient group. In countries with multiple value sets available\, differences in parameters were compared to differences in mean utility. \nResults\nParameters representing value set range had consistently large marginal effects across value sets and patient groups. Increased importance of self-care relative to other dimensions always increased utility\, though with variable effect sizes. The direction and magnitude of the marginal effects of other dimensions’ relative importance varied across value sets and patient groups. The magnitude of all parameters’ marginal effects increased with condition severity.\nIn within-country comparisons the magnitudes of parameter differences were related to utility differences\, with the smallest and largest differences for both seen when comparing the Japanese and Peruvian value sets respectively. Utility differences were increasing in disease severity: the utility of people with the worst chronic pain level differed by 0.425 depending on which Peruvian value set was used. \nConclusion\nThis study presents innovative methods for comparing EQ-5D-5L value sets and assessing what aspects have the biggest impact on patient utilities. Value set range was a major driver of utility differences\, and people with more severe conditions were most likely to be impacted by using alternative value sets. \nSpeaker: \nEd Webb is an associate professor at the Academic Unit of Health Economics\, University of Leeds. He studies preferences and decision-making in a wide variety of contexts and using a range of methods. His other research interests include the measurement and valuation of health\, as well as interactions between health\, work and wellbeing.
URL:https://healtheconomics.org/event/a-new-approach-to-comparing-eq-5d-5l-value-sets-what-really-makes-a-difference-to-people/
LOCATION:Zoom
CATEGORIES:IHEA Event
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=UTC:20260504T153000
DTEND;TZID=UTC:20260504T163000
DTSTAMP:20260425T064724
CREATED:20260423T162906Z
LAST-MODIFIED:20260423T163130Z
UID:335019-1777908600-1777912200@healtheconomics.org
SUMMARY:Do GLP-1 Medications Pay for Themselves?
DESCRIPTION:Add to Calendar! \nGlucagon-like peptide-1 receptor agonists (GLP-1s) represent a major improvement in treatment of diabetes\, obesity\, and cardiovascular risk reduction\, but they are also among the most expensive drugs in widespread use and the subject of significant policy debate. The high price of these drugs may overstate their net cost if the health improvements they produce lead to reduced downstream health care use and medical spending\, that is\, cost offsets. We estimate such offsets using insurance claims data\, examining the effects of GLP-1 initiation on subsequent GLP-1 use and spending\, and on other non-GLP-1 spending. We use a stacked difference-in-differences design\, comparing patients initiating GLP-1 medication to not-yet-treated controls who initiate GLP-1s several months or years later\, allowing us to control for underlying time trends and baseline characteristics. Overall\, we do not find a reduction in downstream medical spending. Although GLP-1 initiation reduces spending on other diabetes medications\, total non-GLP-1 spending increases\, driven by higher outpatient health care use; GLP- 1 drug spending rises mechanically. For health care payers\, the relevant cost of GLP-1 initiation therefore extends beyond the sticker price of the drug. We find similar results across subgroups of GLP1 initiators including those with prior cardiovascular disease and those without diabetes (consistent with obesity indication). Our main results examine spending responses over the first year after initiation. However\, we also estimate longer run effects in a smaller sample and find no cost offsets even five years after GLP-1 initiation. Taken together\, these results suggest that payers facing the costs of GLP-1 coverage are unlikely to see large savings from reduced spending on other care. If GLP-1 therapies ultimately yield cost savings\, they are likely to occur only over longer horizons or through non-medical channels. \nSpeaker: \nDr. Kosali Simon is the Herman B Wells Endowed Professor at Indiana University. In 2021\, she was elected to the National Academy of Medicine. Simon is a nationally known health economist who specializes in applying economic analysis in the context of health insurance and health care policy. Her current research mainly focuses on the impact of health insurance reform on healthcare and labor market outcomes\, and on the causes and consequences of the opioid crisis. She is also active in national leadership roles in her profession\, serving on several boards and in editorial positions. A summary of her recent research appears in the 2018 National\nBureau of Economic Research Reporter.
URL:https://healtheconomics.org/event/do-glp-1-medications-pay-for-themselves/
LOCATION:Zoom
CATEGORIES:IHEA Event
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=UTC:20260505T143000
DTEND;TZID=UTC:20260505T153000
DTSTAMP:20260425T064724
CREATED:20260423T142813Z
LAST-MODIFIED:20260423T151309Z
UID:335013-1777991400-1777995000@healtheconomics.org
SUMMARY:Do changes in management practices reduce hospital waiting times? Evidence from a workforce retention programme
DESCRIPTION:Add to Calendar! \nLong before the pandemic\, increasingly longer waiting times for hospital treatment in English NHS has been a challenge\, directly affecting patient outcomes\, service efficiency\, and overall healthcare quality. In this paper\, we develop a theoretical model that links patients’ waiting times for planned treatment to hospital nurses’ retention\, and postulate the possibility of a virtuous loop between these two variables that can be ignited by higher managerial quality. We test these hypotheses by assessing the effects of a national workforce policy on waiting times\, leveraging a synthetic difference-in-difference analysis using detailed patient records for planned care admissions to English NHS hospitals.\nIn line with the predictions\, our results suggest that the policy had indeed improved nurses’ retention\, while also leading to reductions in average waiting times for planned knee replacement surgery and shortens waiting times for all planned procedures. Our results highlight the potential benefits of workforce stability and managerial improvements on healthcare delivery. \nSpeaker: \n \nGiuseppe is a Professor of Economics at the University of Surrey and an empirical economist specialising in health economics\, labour economics\, and applied micro-econometrics. He previously held research positions at the Centre for Health Economics\, University of York\, and before his PhD he has worked in investment banking at Lehman Brothers in London. Giuseppe earned his PhD in Econometrics and Empirical Economics from the University of Rome Tor Vergata\, following undergraduate and master’s degrees from Bocconi University in Milan. \nHis research focuses on generating robust causal evidence to inform health and workforce policy\, with particular expertise in provider choice and competition\, hospital performance\, waiting times\, health inequalities in access to healthcare\, and the economics of the healthcare workforce. From 2019 to 2025\, Giuseppe has been the Principal Investigator of a major Health Foundation–funded programme examining the determinants and impacts of hospital workforce retention in the English NHS. His work is widely published in leading health economics and social science journals.
URL:https://healtheconomics.org/event/do-changes-in-management-practices-reduce-hospital-waiting-times-evidence-from-a-workforce-retention-programm/
LOCATION:Zoom
CATEGORIES:IHEA Event
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=UTC:20260513T120000
DTEND;TZID=UTC:20260513T140000
DTSTAMP:20260425T064724
CREATED:20260417T155858Z
LAST-MODIFIED:20260420T144300Z
UID:334964-1778673600-1778680800@healtheconomics.org
SUMMARY:Health spending and outcomes
DESCRIPTION:Add to Calendar! \nThis web workshop will explore the relationship between health spending and health outcomes\, bringing together empirical evidence from a diverse range of country contexts. Presentations will examine whether increased public investment in health translates into measurable improvements in population health\, drawing on case studies from Brazil\, Indonesia\, the United Kingdom\, the United States\, and South Africa\, alongside a systematic review of existing research. The session will provide participants with a deeper understanding of the key methods and theoretical approaches used to evaluate the impact of health expenditure. It will conclude with dedicated time for questions\, answers\, and open discussion\, offering an opportunity for critical reflection and exchange. \nPresentations: \n\n The effect of public health expenditure on health and health care use: a systematic review\n\n \nThis systematic review and meta-regression analysis synthesizes the international literature on the effect of public health expenditure on health and care. Findings highlight the importance of strong governance\, sustainable financing\, and investment in prevention and workforce\, while revealing key gaps in evidence from low- and middle- income countries and in understanding financing mechanisms. \n  \nPresenter: Eliana Chavarría-Pino is a postdoctoral researcher at the Ludwig Maximilian University of Munich. Her work focuses on the evaluation of health policies and programmes in low- and middle-income countries\, with a particular emphasis on health financing and the health workforce. \n  \n\n The impact of different types of NHS expenditure on health: Marginal cost per QALY estimates for England for 2016/17\n\nThis study examines how different types of NHS spending vary in their ability to generate health gains\, measured in cost per quality-adjusted life year (QALY). Using 2016 data and two-stage least squares\, the authors estimate that locally commissioned services deliver a QALY for around £8\,000\, while results for primary care and specialised services are more uncertain. Accounting for this variation slightly increases the overall estimated cost per QALY across the NHS. The findings suggest that directing additional investment toward primary care and locally commissioned services may yield the greatest health benefits. \nPresenter: James Lomas is a senior lecturer at the Department of Economics and Related Studies at the University of York. His research is focused on applied microeconometric analysis that answers the empirical questions posed in the context of economic evaluation and cost-effectiveness analysis.  \n  \n\n Health system efficiency under fiscal constraint: Spending complementarity and district performance in South Africa\n\n \nThis study evaluates how efficiently public health funds are used across 48 districts in South Africa amid tight fiscal constraints. Using stochastic frontier analysis\, it finds wide variation in efficiency (7%–87%)\, with significant potential to improve health outcomes without increasing spending. Results highlight that primary health care spending is most effective when supported by sufficient hospital capacity\, while hospital spending shows more consistent benefits. The study identifies district performance patterns to guide better resource allocation and peer learning in constrained health systems. \nPresenter: Fouché Venter is Executive Director of Economic Research Southern Africa and an applied economist focused on public economics. His research examines fiscal sustainability\, fiscal frameworks\, and the efficiency and effectiveness of public resource allocation. \n  \n\n Does Increasing Public Spending in Health Improve Health? Lessons from a Constitutional Reform in Brazil\n\nThis presentation discusses how government health spending shapes health outcomes by exploring unique top-down variation generated by Brazil’s 29th Constitutional Amendment\, which mandated minimum thresholds for municipal health spending. It describes how sharp changes in health spending resulting from the Constitutional Amendment affect downstream outcomes\, documenting increases in available resources and access to health at various margins\, with resulting declines in infant mortality and all cause mortality. Secondly\, it discusses the production function of public healthcare\, documenting non-linearities and input complementarities.  A number of key margins of spending effectiveness and constraints to larger gains from health spending are highlighted\, including frictions between bureaucratic capacity and political incentives. \nPresenter: Damian Clarke is a researcher and Associate Professor of Economics at The University of Exeter\, and The University of Chile. His research focuses on maternal and child health\, and family fertility decisions. In particular\, his papers examine the impact of public programs on maternal mortality and morbidity\, early life health outcomes for children\, and the determinants of parental investment in children. \n  \n\n Does increasing overall health expenditure reduce inequality in under-5 mortality rates between provinces in Indonesia?\n\nThis study analyses whether increased public health spending in Indonesia (2004–2012) reduced inequalities in under-five mortality across socioeconomic groups. Using dynamic panel System-GMM and instrumental variables\, it finds that higher spending actually widened inequality\, as wealthier households benefited more from mortality reductions than poorer ones. The study finds no significant difference in impact between provinces with high and low baseline mortality. Overall\, the results suggest that simply increasing health spending is insufficient to reduce inequalities unless funds are better targeted toward disadvantaged populations and high-need areas. \nPresenter: Ivan Ochoa-Moreno is a Research Fellow in Global Health at the University of York. His research focuses on impact evaluation of health policies\, universalisation of healthcare and lifelong impact of early-life health and development. \n  \n\n The Value of Healthcare in the United States: Changes in Lifetime Spending and Health-Adjusted Life Expectancy\, 1996 to 2016\n\nThis study extends prior work on the value of healthcare spending by examining health-adjusted life expectancy (HALE) and lifetime costs across all ages and diseases. Using global burden and expenditure data\, it estimates that healthcare improvements from 1996 to 2016 increased HALE by about 1.3 years at a cost of roughly $182\,000 per HALE gained. Results vary widely by disease\, with substantial gains for conditions like HIV/AIDS and heart disease\, but negative effects for drug use disorders. The findings highlight the importance of evaluating healthcare value across the full life course and by specific causes. \nPresenter: Marcia Weaver\, PhD\, is a Research Professor of Health Metrics Sciences at the Institute for Health Metrics and Evaluation (IHME) at the University of Washington where she leads the cost-effectiveness research team. She specialises in meta-regression analysis of published cost-effectiveness estimates and has published 103 peer-reviewed articles. 
URL:https://healtheconomics.org/event/health-spending-and-outcomes/
LOCATION:Zoom
CATEGORIES:IHEA Event
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=UTC:20260525T050000
DTEND;TZID=UTC:20260525T060000
DTSTAMP:20260425T064724
CREATED:20260420T172146Z
LAST-MODIFIED:20260420T172146Z
UID:334975-1779685200-1779688800@healtheconomics.org
SUMMARY:A 10-year scoping review: an inspirational or cautionary tale?
DESCRIPTION:Add to Calendar! \nEver started a project that was meant to be ‘quick and straightforward’? In this webinar\, Associate Professor Nikki McCaffrey will share the story behind a scoping review that took almost a decade to complete before publication in Social Science & Medicine. The talk offers a candid\, slightly irreverent look at scope creep\, opportunity cost\, and the hard calls around when to persist\, pivot\, or cut losses. Short\, honest\, and practical\, with reassurance that messy research journeys are far more common than we admit. \nSpeaker: \nAssociate Professor Nikki McCaffrey is a health economist at Deakin University\, Victoria\, Australia and Head of Cancer Economics. She works at the intersection of health economics\, outcomes research and policy\, with a particular focus on cancer\, palliative and end‑of‑life care\, and the often‑overlooked role of informal carers. Nikki has published 100+ peer‑reviewed papers and secured over $20 million in competitive research funding\, leading multidisciplinary teams across Australia and internationally. She is a co‑founder and co‑lead of the International Health Economics Association Special Interest Group on the Economics of Palliative & End‑of‑Life Care\, and is a strong advocate for applied\, decision‑relevant research that actually gets used.
URL:https://healtheconomics.org/event/a-10-year-scoping-review-an-inspirational-or-cautionary-tale/
LOCATION:Zoom
CATEGORIES:IHEA Event
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=UTC:20260528T080000
DTEND;TZID=UTC:20260528T090000
DTSTAMP:20260425T064724
CREATED:20260325T193218Z
LAST-MODIFIED:20260325T193218Z
UID:334808-1779955200-1779958800@healtheconomics.org
SUMMARY:Biobanks and Genomics in Low- and Middle-Income Countries: Emerging Opportunities for Research and Health Economics Webinar & Panel Discussion
DESCRIPTION:Add to Calendar! \nThis panel discussion will feature short presentations from Professor Segun Fatumo (Chair of Genomic Diversity at Queen Mary University of London and Head of Non-Communicable Disease Genomics at the MRC Uganda Research Unit) and Professor Zhu Chen (College of Economics and Management\, China Agricultural University\, Beijing). The speakers will highlight emerging opportunities in biobanks and genomics\, particularly in low- and middle-income country (LMIC) settings. The panel discussion will then explore how biobank and genomic platforms and data can be leveraged to inform health economic analysis and policy decision-making in LMICs\, followed by an open discussion and concluding remarks. \nModerator: Professor Zanfina Ademi\, Monash University \nPresentation 1:\nName: Professor Segun Fatumo\nRole & organization: Chair of Genomic Diversity at Queen Mary University of London and Head of Non-Communicable Disease Genomics at the MRC Uganda Research Unit\nBio: Professor Segun Fatumo is a globally recognised genomic epidemiologist advancing equitable human genomics research. He is Professor and Chair of Genomic Diversity at Queen Mary University of London and Head of Non-Communicable Disease Genomics at the MRC Uganda Research Unit. His work focuses on genetic determinants of cardiometabolic disease and kidney disease in diverse ancestry populations. He leads major initiatives including KidneyGenAfrica\, BCX-Africa and the Nigerian 100K Genome Project\, supported by international funders such as the MRC\, NIH and Wellcome Trust. Professor Fatumo is widely published\, serves on global advisory boards\, contributes to genomics policy and capacity building in Africa\, and is a frequent keynote speaker and media commentator\nAbstract: The Uganda Genome Resource (UGR) is a well-characterized genomic biobank derived from the long-standing Uganda General Population Cohort\, comprising genotype data (~5\,000 individuals) and whole-genome sequencing (~2\,000 individuals) across 10 ethno-linguistic groups. With rich phenotypic data spanning communicable and non-communicable diseases\, UGR provides a unique platform for advancing genomics\, multi-omics integration\, and precision medicine in African populations. It enables discovery of population-specific variants\, improved disease risk prediction\, and deeper biological insights across diverse ancestries. These opportunities position UGR as a critical resource not only for scientific discovery but also for generating evidence to inform cost-effective health economic strategies and policy decisions in LMICs. \nPresentation 2:\nName: Professor Chen Zhu\nRole & organization: College of Economics and Management\, China Agricultural University\, Beijing\nBio: Chen Zhu is a Professor at the College of Economics and Management\, China Agricultural University. She received her Ph.D. in Agricultural and Resource Economics from the University of Connecticut and her B.S. in Biology from Nanjing University. She currently serves as an Associate Editor for Agribusiness and an Editorial Board Member of Scientific Reports. Dr. Zhu has published more than 50 peer-reviewed articles in economics\, public health\, and interdisciplinary journals. Her research focuses on genoeconomics\, integrating genetic and socioeconomic data to better understand human capital formation\, health behaviors\, and economic decision-making\, with particular interest in applications to rural development and health policy in China. Website: https://zhuchencau.wordpress.com/cv/\nAbstract: This talk introduces a pilot Human Capital and Genoeconomics Survey conducted among rural households in China since 2019. The survey combines rich socioeconomic information\, including human capital\, health behaviors\, fertility\, and household decision-making\, with individual genetic data for about 800 participants in rural China. Using this dataset\, she will explore how genomic variation interacts with environmental conditions\, nutrition\, and local economic contexts to shape health and socioeconomic outcomes. She will argue that small- and medium-scale genomic surveys linked to detailed socioeconomic data can complement large biobanks\, offering a practical framework for advancing genoeconomics research and informing health and development policy in low- and middle-income country settings.
URL:https://healtheconomics.org/event/biobanks-and-genomics-in-low-and-middle-income-countries-emerging-opportunities-for-research-and-health-economics-webinar-panel-discussion/
LOCATION:Zoom
CATEGORIES:IHEA Event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20260606
DTEND;VALUE=DATE:20260612
DTSTAMP:20260425T064724
CREATED:20251116T003732Z
LAST-MODIFIED:20251116T005959Z
UID:334343-1780704000-1781222399@healtheconomics.org
SUMMARY:ASHEcon 2026 Annual Conference
DESCRIPTION:
URL:https://healtheconomics.org/event/ashecon-2026-annual-conference/
CATEGORIES:External Event
END:VEVENT
END:VCALENDAR